exonuclease 5Genealiases: C1orf176 · DEM1 · Exo V · hExo5
Q-omics provides the consensus-scored EXO5 profile across patient tissues and cancer cell-line models. EXO5 expression is associated with patient survival in 20 of 34 cancer types, with the highest sampling consensus in ACC. Among the 18 cancer types available for tumor–normal comparison, EXO5 is differentially expressed in 12, with the highest sampling consensus in KICH. Additionally, EXO5 RNA expression shows 19,384 significant gene co-expression associations, with the highest sampling consensus in ACC. Together, these results highlight ACC, and KICH as cancer lineages where EXO5 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for EXO5 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes EXO5 survival associations across molecular data types. EXO5 RNA expression shows survival associations in the most cancer types (20), followed by mutation status (2). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible EXO5 RNA expression–survival associations across cancer types. High EXO5 expression shows unfavorable associations in ACC, MESO and LIHC, but favorable associations in KIRC, OV and HNSC. The ACC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify ACC as the clearest survival context for EXO5 RNA expression.
This table summarizes EXO5 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 12. The strongest signals are observed in KICH for RNA.
This table ranks reproducible tumor–normal expression differences for EXO5. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. EXO5 shows lower tumor expression in KICH and higher tumor expression in LIHC, LUAD, BLCA, LUSC and HNSC. The KICH box plot shows higher EXO5 RNA expression in normal versus tumor tissue (log2 FC = −1.537, t-test p < 0.001).
This table shows molecular features associated with EXO5 in patient tissues and cancer cell lines. In patient samples, EXO5 shows the broadest associations at the RNA and protein expression levels, with ACC recurring as the lineage with the largest associated feature set. In cancer cell lines, EXO5 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in SKIN, while CRISPR and shRNA rows add functional-dependency signals in LUNG_SCLC and BLOOD_Leukemia.
